Switch theme
Sign up to access all valuation multiples
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
1954
16.2K+
LTM Revenue $4.2B
LTM EBITDA $1.3B
$25.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Coloplast has a last 12-month revenue (LTM) of $4.2B and a last 12-month EBITDA of $1.3B.
In the most recent fiscal year, Coloplast achieved revenue of $4.1B and an EBITDA of $1.3B.
Coloplast expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Coloplast valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.2B | XXX | $4.1B | XXX | XXX | XXX |
| Gross Profit | $2.8B | XXX | $2.8B | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 68% | XXX | XXX | XXX |
| EBITDA | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 31% | XXX | XXX | XXX |
| EBIT | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EBIT Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| Net Profit | $690M | XXX | $761M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 19% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $3.1B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Coloplast's stock price is DKK 636 (or $96).
Coloplast has current market cap of DKK 143B (or $21.6B), and EV of DKK 167B (or $25.1B).
See Coloplast trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $25.1B | $21.6B | XXX | XXX | XXX | XXX | $3.37 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Coloplast has market cap of $21.6B and EV of $25.1B.
Coloplast's trades at 6.1x EV/Revenue multiple, and 19.4x EV/EBITDA.
Equity research analysts estimate Coloplast's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Coloplast has a P/E ratio of 31.3x.
See valuation multiples for Coloplast and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $21.6B | XXX | $21.6B | XXX | XXX | XXX |
| EV (current) | $25.1B | XXX | $25.1B | XXX | XXX | XXX |
| EV/Revenue | 6.0x | XXX | 6.1x | XXX | XXX | XXX |
| EV/EBITDA | 18.8x | XXX | 19.4x | XXX | XXX | XXX |
| EV/EBIT | 22.0x | XXX | 22.5x | XXX | XXX | XXX |
| EV/Gross Profit | 8.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 31.3x | XXX | 29.4x | XXX | XXX | XXX |
| EV/FCF | 46.0x | XXX | 75.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialColoplast's last 12 month revenue growth is 7%
Coloplast's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Coloplast's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Coloplast's rule of X is 49% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Coloplast and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | 38% | XXX | 38% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 49% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 41% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Coloplast acquired XXX companies to date.
Last acquisition by Coloplast was XXXXXXXX, XXXXX XXXXX XXXXXX . Coloplast acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Coloplast founded? | Coloplast was founded in 1954. |
| Where is Coloplast headquartered? | Coloplast is headquartered in Denmark. |
| How many employees does Coloplast have? | As of today, Coloplast has 16.2K+ employees. |
| Who is the CEO of Coloplast? | Coloplast's CEO is Mr. Kristian Villumsen. |
| Is Coloplast publicy listed? | Yes, Coloplast is a public company listed on CSE. |
| What is the stock symbol of Coloplast? | Coloplast trades under COLO B ticker. |
| When did Coloplast go public? | Coloplast went public in 1993. |
| Who are competitors of Coloplast? | Similar companies to Coloplast include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Coloplast? | Coloplast's current market cap is $21.6B |
| What is the current revenue of Coloplast? | Coloplast's last 12 months revenue is $4.2B. |
| What is the current revenue growth of Coloplast? | Coloplast revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Coloplast? | Current revenue multiple of Coloplast is 6.0x. |
| Is Coloplast profitable? | Yes, Coloplast is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Coloplast? | Coloplast's last 12 months EBITDA is $1.3B. |
| What is Coloplast's EBITDA margin? | Coloplast's last 12 months EBITDA margin is 32%. |
| What is the current EV/EBITDA multiple of Coloplast? | Current EBITDA multiple of Coloplast is 18.8x. |
| What is the current FCF of Coloplast? | Coloplast's last 12 months FCF is $546M. |
| What is Coloplast's FCF margin? | Coloplast's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of Coloplast? | Current FCF multiple of Coloplast is 46.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
